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All Patients ( = 14) 
Bone marrow ( = 10) 
Other source ( = 4) 
 < 0.001 
EDSS ≥ 6 ( = 5) 
EDSS < 6 (= 9) 
 = 0.048  = 0.008 
A B 
C D EDSS < 6 w/o tx complications ( = 6) 
EDSS ≥ 6 or tx complications ( = 8) 
Page 1 of 53
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
  
 
 
 
Cognition stable between dx ACALD and HSCT? 
No 
pts. #02H, 11P, 12P 
 
OS = 1/3 
EFS = 0/3 
EDSS  ≥ 6 
pts. #01B, 04S, 08B, 09B, 13P 
 
OS = 1/5 (20%) 
EFS* = 0/5 (0%) 
EDSS  < 6 
pts. #02H, 03B, 05B, 06B, 07B, 
10B, 11P, 12P, 14P 
OS = 7/9 (78%) 
EFS = 4/9 (44%)  
No 
pts. #01B, 04S, 09B 
OS = 1/3 
EFS = 0/3 
Yes 
pts. #02H, 03B, 05B, 06B 
10B, 11P, 12P, 14P 
OS = 6/8 (75%) 
EFS = 4/8 (50%)  
Yes 
pts. #08B, 13P 
OS = 0/2 
No 
pt. #09B 
OS = 0/1 
Yes 
pts. #01B, 04S 
OS = 1/2 
EFS = 0/2 
No 
pts. #08B, 13P 
OS = 0/2 
EDSS before HSCT? 
Yes 
pt. #07B 
 
OS = 1/1 
EFS = 0/1 
Yes 
pts. #03B, 05B, 06B 
10B, 14P 
OS = 5/5 (100%) 
EFS = 4/5 (80%) 
Without transplant complications? 
No 
pt. #07B 
 
OS = 1/1 
EFS = 0/1 
Page 2 of 53
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
  
 
 


		

 
 
Page 3 of 53
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
	
	


	
	









JörnSven Kühl
1*
, Felipe Suarez
2*
, Godfrey T. Gillett
3
, Philipp G. Hemmati
4
, John A. 
Snowden
5
, Michael Stadler
6
, Giang L. Vuong
4
, Patrick Aubourg
7*
, Wolfgang Köhler
8*
, 
Renate Arnold
4*
 




* 








P.A. and W.K. initiated, screened and evaluated the French and German patients, 
respectively, while F.S. and R.A. were responsible for transplanting the French and 
German patients, respectively. J.S.K. organized the German series, collected, and analyzed 
data and wrote the manuscript with P.A and W.K. 
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The adult cerebral inflammatory form of Xlinked adrenoleukodystrophy is a rapidly 
progressive neurodegenerative disease, as devastating as childhood cerebral 
adrenoleukodystrophy. While Allogeneic hematopoietic stem cell transplantation has been 
demonstrated to provide longterm neurological benefits for boys with the childhood cerebral 
form, but results in adults are sparse and inconclusive.  
We collected and retrospectively analyzed data from 14 adult males with adult cerebral 
adrenoleukodystrophy who had been treated with allogeneic hematopoietic stem cell 
transplantation on a compassionate basis in four European centres. All presented with 
progression of cerebral demyelinating lesions and gadolinium enhancement. Median age at 
diagnosis of adult cerebral adrenoleukodystrophy was 33 years (range 21  48 years)
 In 
addition to cerebral inflammation
 five patients presented with had established severe motor 
disability from adrenomyeloneuropathy affecting only the spinal cord and peripheral nerves 
(expanded disability status scale score ≥ 6).  
Eight patients survived (estimated survival 57 ± 13 %) with a median followup of 65 months 
(minimum 38 months). Death was directly transplant/infection related ( = 3), due to 
primary disease progression in advanced adult cerebral adrenoleukodystrophy ( = 1), or 
secondary disease progression ( = 2) after transient multiorgan failure or nonengraftment 
respectively. Specific complications during stem cell transplantation included deterioration of 
motor and bladder functions ( = 12) as well as behavioural changes ( = 8). Whilst Arrest of 
progressive cerebral demyelination and prevention of severe loss of neurocognition was 
achieved in all eight survivors, but deterioration of motor function occurred in the majority ( 
= 5). Limited motor dysfunction (expanded disability status scale score < 6) prior to stem cell 
transplantation was associated with significantly improved survival (78 ± 14 % [ = 9] versus 
20 ± 18 % [ = 5];  < 0.05) and maintenance of ambulation (expanded disability status scale 
score < 7) posttransplant (78 % versus 0 %;  = 0.021). In contrast, bilateral involvement of 
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the internal capsule on brain MRI was associated with poorer survival (20 ± 18 % [ = 5] 
versus 78 ± 14 % [ = 9]; < 0.05).
This study is the first to support the feasibility, complications and potential longterm 
neurological benefit of allogeneic hematopoietic stem cell transplantation in adult cerebral 
adrenoleukodystrophy. Further studies are warranted to attempt to improve outcomes through 
patient selection and optimisation of transplantation protocols. Given the rarity of this disease, 
it is essential to have clear referral pathways to specialist centres able to assess and treat 
patients without delay. 
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Xlinked adrenoleukodystrophy; adult cerebral form; hematopoietic stem cell 
transplantation; brain MRI; longterm outcome 
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AACS = adult XALD clinical symptom score;
ACALD = adult cerebral 
inflammatory form of Xlinked adrenoleukodystrophy;
AMN = adrenomyeloneuropathy; 
CCALD = childhood cerebral inflammatory form of Xlinked adrenoleukodystrophy;
EDSS = 
Kurtzke expanded disability status scale;
GVHD = graftversushost disease;
HSCT = 
hematopoietic stem cell transplantation;
IQ = intelligence quotient;
XALD = Xlinked 
adrenoleukodystrophy

Page 8 of 53
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
$

Xlinked adrenoleukodystrophy (XALD) is an inherited peroxisomal disorder caused by a 
defective  gene
leading to a characteristic accumulation of saturated very long chain 
fatty acids in blood and tissues. The white matter in the brain, spinal cord, adrenal cortex, 
Leydig cells and hair follicles is typically affected tissues (Moser, 1997; Kemp	
, 2012; 
Wiesinger 	
 , 2015). With an estimated combined incidence of 1:17,000 in men and 
women XALD is one of the commonest most prevalent inborn peroxisomal diseases.  
Although there is a pronounced phenotypic variation may occur within kindreds, two major 
forms of XALD can be differentiated (Moser, 1997; Kemp 	
 , 2012; Wiesinger 	
 , 
2015). Firstly, a chronic neuronopathic form, called adrenomyeloneuropathy (AMN), 
involving spinal cord and to a lesser extent peripheral nerves in adult males as well as 
heterozygous females, and characterized by a slowly progressive spastic paraplegia with 
sensory ataxia. Secondly, a cerebral demyelinating variant with neuroinflammation that 
causes rapid white matter destruction. Cerebral demyelination results in rapid loss of 
neurocognitive, motor and sensory functions with vegetative state and death following within 
months to a few years of onset. To date, no triggers or other factors have been identified to 
predict the onset of this acute inflammatory cerebral form of XALD, which affects about a 
third of all males in childhood (childhood onset cerebral ALD, CCALD). Although a Primary 
isolated cerebral disease in adolescence or adulthood is relatively uncommon (5  10 %), 
although up to 63 % of men suffering from with AMN develop secondary cerebral 
inflammatory demyelination within 10  15 years (de Beer	
, 2014). For the purposes of 
this study, primary and secondary cerebral demyelination with gadolinium enhancement of 
lesions in adulthood will be is termed adult cerebral ALD (ACALD). ACALD is as 
devastating as CCALD: with patients rapidly lose cognitive and motor function leading to 
death.  
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Allogeneic hematopoietic stem cell transplantation (HSCT) is an established longterm 
treatment method in boys with CCALD (Aubourg	
, 1990; Shapiro	
, 2000; Baumann
	
 , 2003; Peters	
 , 2004; Beam 	
, 2007; Miller 	
 , 2011), although the exact 
mechanism of action is not fully understood (Moser and Mahmood, 2007; Schonberger	
, 
2007; Cartier 	
 , 2014)
 Survival and neurological outcome of CCALD patients after 
HSCT is clearly superior compared to untreated patients (Mahmood	
, 2007; Miller	
, 
2011). Despite the significant risks of HSCT, there is no other effective therapeutic option 
exists for CCALD. In ACALD, there are Only a few anecdotal reports of allogeneic HSCT in 
ACALD are available with inconclusive results (Hitomi	
, 2005; Fitzpatrick	
, 2008). 
In contrast to boys, the cerebral form in men is usually associated with motor and sensory 
deficits in the lower limbs as well as bladder dysfunction resulting from as a consequence of 
the AMN. The pattern of CNS demyelination in adults may also be different (Loes 	
 , 
2003; Eichler 	
, 2007). Moreover, bone marrowderived cells infiltrating the brain may 
react differently in older patients (Barrett 	
 , 2015)
 Nevertheless, The extremely poor 
prognosis with a median overall survival of 2 years once ACALD enters the phase of active 
neuroinflammation (van Geel	
, 2001; de Beer	
, 2014), combined with lack of any 
other effective treatment, has justified the extension of allogeneic HSCT into the older age 
group. with the aim of reducing the rate of disease progression and death. 
We report here a retrospective analysis of the feasibility, toxicity and longterm neurological 
outcomes of 14 adult males treated with allogeneic HSCT for ACALD on an individually 
selected compassionate basis in four European centres. Based on our combined experience, 
we propose some preliminary guidelines for patient selection and treatment protocols for 
allogeneic HSCT in this setting. and identify future areas for research and development.  
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Fourteen adult males underwent HSCT for ACALD in four hematopoietic stem cell transplant 
centres in Germany, France and UK. Diagnosis of XALD was based on elevated 
concentrations of fasting plasma very long chain fatty acids, and additionally on mutations of 
the gene (HGNC: 61) in nine patients. Diagnosis of ACALD required the detection of 
gadolinium enhancement in cerebral demyelinating lesions by brain MRI.  
Patient characteristics are summarized in table 1. Patients had detailed neurological, 
neurophysiological, and neuropsychological evaluation as well as MRI exams before and 
sequentially after HSCT. All patients were offered HSCT on an individually selected 
compassionate basis in accordance with the practice guidelines of the Working Party on 
Inborn Errors of the European Group for Blood and Marrow Transplantation (Peters and 
Steward, 2003) and after providing with written informed consent for HSCT. In addition The 
use of stem cell collections from unrelated donors and cord blood, where appropriate, were 
approved by the medical advisory boards of the respective national donor search programs for 
this indication. 
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Twelve out of 14 patients received allogeneic HSCT from a matched donor after 
myeloablative conditioning. A matched donor was either a genotypical HLAidentical sibling 
( = 3) or a ≥ 9/10 HLAmatched unrelated donor ( = 9) confirmed by highresolution DNA 
typing of HLA class I (HLA A, B, Cw) and class II (HLA DRB1, DQB1) alleles. Ten of these 
12 patients were transplanted with bone marrow, and two patients received granulocyte
colony stimulating factor (GCSF) mobilised peripheral blood stem cells based on donor 
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preference. Myeloablative conditioning consisted of busulfan and cyclophosphamide. In two 
patients there was an inability it was not possible to identify a suitably HLAmatched donor, 
and they underwent unrelated cord blood transplantation after reducedintensity conditioning. 
All but two patients received additional serotherapy for graftversushost disease (GVHD) 
prophylaxis: polyclonal antithymocyte globulin from Genzyme® (Saint Germain en Laye, 
France;  = 1), Fresenius® (Fresenius Biotech, Gräfelfing, Germany;  = 10), or the 
monoclonal antibody alemtuzumab (from Genzyme®;  = 1). Basic transplant characteristics 
of all patients are summarized in table 2. GVHD prophylaxis and supportive care measures 
were delivered according to standard of care protocols at the individual centres. 
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Engraftment with full donor chimerism was defined as > 90% donor cells in total nucleated 
cells at day +100 postHSCT as detected by DNAbased techniques (i.e. short tandem repeats 
analysis). Diagnosis of acute GVHD was primarily based on clinical criteria; overall staging 
of acute and chronic GVHD was done according to published criteria. Transplant toxicity was 
described according to the National Cancer Institute common terminology criteria for adverse 
events version 3.0 (CTCAE v.3.0) with severe toxicity recorded for adverse events grade ≥ 3.  
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Patientrelated clinical information was obtained from retrospective review of medical records 
in each transplant centre as well as and from their neurologists.  
To analyse changes in disease status, the following Assessment tools were used to analyse 
changes in disease status: the Adult XALD Clinical Symptom score (AACS) (Köhler and 
Sokolowski, 1999) to quantify the overall XALD neurological impairment, the Kurtzke 
Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) to assess motor dysfunction, the 
modified Rankin scale (Rankin, 1957) to describe disability status in daily activities, and the 
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Loes MRI severity score (Loes	
, 1994) to measure the extent of cerebral demyelination. 
Detailed Neurological examination covered the following areas: motor function, sensation, 
bladder function, as well as overall CNS function including vision, hearing, and speech. 
Based on these evaluations and from transplant records scores for AACS, EDSS, and 
modified Rankin scale were assigned determined for the time points preHSCT, worst status 
during first 6 months postHSCT, and status approximately 24 months postHSCT (minimum 
≥ 12 months) for evaluable patients. In four patients (#01B, #03B, #04S, and #07B), no MRI 
scans were available before the onset of ACALD, while in three patients (#12P, #08B, and 
#09B), postHSCT MRI could not be obtained due to poor clinical status and early death. In 
addition to Loes score, MRI scans were reviewed for gadolinium enhancement and patterns of 
demyelination (parietooccipital ± long tract pyramidal involvement versus all other patterns). 
Furthermore, Lesion progression was calculated from sequential MRI scans. 
Neuropsychometric assessment was performed preHSCT and, whenever possible, at various 
time points postHSCT. Normalized measures of intelligence quotient (IQ) were generated by 
appropriate tools according to the centres’ preference. 
Patients unable to walk without aid or rest for about 100 meters (EDSS ≥ 6), were classified 
as advanced AMN. Stable motor function postHSCT was defined as increment in EDSS < 1 
point with preserved/maintained ambulation (EDSS < 7). Severe deterioration in motor 
function was classified as increment in EDSS ≥ 2 points or to EDSS ≥ 7. Stable 
neurocognition postHSCT was defined as deterioration in IQ < 15 ( < 1 standard deviation) 
or no relevant cognitive deterioration as detected by caregivers; severe deterioration in 
intellectual function was classified as obvious cognitive decline or inability to test for IQ 
anymore. Moderate deterioration was defined as any deterioration less than severe. For the 
purpose of this study, events were defined in relation to ACALD progression, i.e. eventfree 
survival was used in this study for surviving patients who retained a stable cognitive function 
after HSCT. 
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Survival was compared by KaplanMeier estimates, and comparisons done by the logrank 
method. Categorical variables were compared using the ztest or Fisher’s exact test. 
Comparison of continuous variables was performed by nonparametric tests (MannWhitney 
signed rank test, the KruskalWallis ANOVA with following pairwise comparisons 
according to Dunn’s method).  Before/after analyses were performed for single time points 
with the Wilcoxon signed rank test or for multiple time points with the Friedman repeated 
measures ANOVA followed by multiple pairwise comparisons according to the Tukey’s test. 
Calculations were done using Sigmaplot 11.0 (Systat Inc., San José, CA, U.S.A.).  
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Fourteen ACALD patients transplanted between 2003 and 2012 at a median age of 34 years 
(range 21 – 48 years) were included in this study. Characteristics of HSCT are summarized in 
table 2.  
Eight of the 14 patients were alive with a median followup of 65 months (range 38 – 116 
months). The estimated overall survival probability was 57.1 ± 13.2 % (mean ± standard 
deviation) (Fig. 1A). There were no survivors after cord blood transplantation with reduced 
intensity conditioning ( = 2) nor after myeloablative conditioning and peripheral blood stem 
cell transplantation ( = 2), while eight out of 10 men after myeloablative conditioning and 
bone marrow transplantation survived (estimated survival probability 80.0 ± 12.6 % (logrank 
test 11.48,  < 0.001) (Fig. 1B). The small numbers did not permit detection of relevant 
transplant differences between patients with matched donors.  
Full donor chimerism ( > 90% donor cells) was detected in 10 out of 11 evaluable patients 
receiving myeloablative conditioning; one patient showed 80 % donor cells (table 2). One 
patient with early fatal complications was not tested. Two men who received cord blood after 
reduced intensity conditioning did not permanently engraft. Among In the 12 patients 
receiving myeloablative conditioning, neutrophil recovery (peripheral neutrophil count ≥ 
500/µl for 3 consecutive days) occurred at a median of 19.5 days (range: 10 – 34 days). (data 
not shown). The incidence of severe GVHD was low: only one patient (8 % of all men 
engrafting with donor cells) developed acute GVHD grade ≥ II (grade 4 of the skin), while 
chronic GVHD was observed in limited form only in four patients. 
There was one death from primary disease progression without relevant HSCT complications 
(patient #4S). Two further patients died from secondary disease progression after life
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threatening infections with transient multiorgan failure (patient #2H) or graftrejection 
(patient #13P). Three early deaths (21 %) were directly transplant or infection related, either 
associated with nonengraftment (patient #12P) or immobility due to advanced AMN 
(patients #8B and #9B).  
Survival was related to baseline motor dysfunction prior to HSCT: limited AMN (EDSS < 6) 
was significantly associated with superior survival compared with advanced AMN (estimated 
survival probability 77.8 ± 13.9 % ( = 9) versus 20.0 ± 17.9 % ( = 5); logrank test 3.91,  
= 0.048; Fig. 1C). After excluding from the analysis the two patients who failed to engraft, the 
EDSS gained further prognostic significance with the estimated survival probability 
increasing to 87.5 ± 11.7 % ( = 8) for EDSS < 6 versus 25.0 ± 21.7 % ( = 4) for EDSS ≥ 6 
(logrank test 5.16,  = 0.003). (data not shown).    
 
'




*


	



Basic Disease characteristics of the 14 ACALD men before HSCT are summarized in table 1. 
Cerebral disease was first detected at a median age of 33 years (range: 21 – 48 years). Ten X
ALD men had been followed monitored in the years before the onset of ACALD. Four 
patients were first diagnosed with Addison’s disease during adolescence (median age at 
diagnosis 16.5 years (range: 10 – 18 years)) in the absence of AMN at that time. Two patients 
had been diagnosed with AMN at the age of 24 and 31 years because of spastic paraparesis. 
and Three patients were identified by family screening with either no symptoms (#10B; age 
15 years), increasing learning difficulties (#14P; age 18 years), or gait disturbances in 
combination with undiagnosed Addison’s disease (#8B; age 23 years). At diagnosis of X
ALD trait, patient #14P presented with extensive parietooccipital leukodystrophy and marked 
ventricular dilatation but without gadolinium enhancement as indication for arrested CCALD 
at that time. The median period between diagnosis of XALD and onset of CNS inflammation 
ACALD was 132 months (range: 19 – 266 months) among these 10 patients. In contrast, four 
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patients (#1B, #3B, #4S, and #7B) already had evidence of ACALD at their first MRI 
examination. Although patient #4S had been originally diagnosed at the age of 24 years by 
family screening, he was not seen again until 8 years later at which stage he had developed 
visual and auditory deficits and ataxia. Patient #7B presented with seizures as first symptom. 
The history of AMN symptoms among these four tended to be shorter than in the other 10 
patients (median duration 15.5 months versus 37 months; = 0.088).  
At detection of cerebral disease, All but one patient (#14P) presented with AMN symptoms, 
which varied considerably in duration (median 24 months, range 0  266 months) and 
severity: while three patients were already severely impaired by had severe motor dysfunction 
(EDSS ≥ 6), two patients displayed no motor dysfunction, at all and two others showed only a 
mild limitation in running. There was no correlation between EDSS and age, but some linear 
correlation between duration of AMN symptoms and EDSS was observed (r = 0.735;  = 
0.003). Bladder dysfunction was also common and present in 12 patients, with marked 
impairment in two of them. Sensory dysfunction was overall mild in 13 patients and in patient 
#6B mild par/hypoesthesia was the only AMN symptom.  
The median interval from detection of ACALD to HSCT was 9 months (range 3 15 months). 
During this period there was a relevant clinical disease progression in six patients: AMN 
symptoms  one, cognition  two, both motor and cognitive functions  three patients. Patient 
#6B developed a visual field defect, while IQ remained stable. Patient #14P still had a strictly 
normal neurological exam even before HSCT, while five other patients presented with severe 
motor disability (EDSS ≥ 6). With regard to occupational status, five men had discontinued 
their established work/profession at onset of ACALD, four of them because of progressive 
motor dysfunction. In the period prior to HSCT, four more patients were unable to continue 
working mainly due to neurocognitive decline. In addition, three men had developed severe 
weight loss before HSCT, in patient #5B at least in part due to a lowfat diet in combination 
with “Lorenzo’s oil”.  
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The median IQ before HSCT was 99 (range 72 – 139). Cognitive deterioration was suspected 
or reported by relatives in all four patients who showed ACALD in their first brain MRI. 
Neuropsychological evaluation before HSCT in these patients also suggested deterioration by 
revealing better verbal IQs than performance IQs (data not shown). However, seven out of the 
10 patients who were followed up longterm displayed no relevant IQ changes until admission 
for HSCT ( = 0.018).  
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Significant neurological and/or behavioural changes were observed during the transplant 
procedure and early followup in all but one ACALD patients (table 3).  
Exacerbation of motor disability during the first 6 months postHSCT was a characteristic 
feature observed in 12 out of 14 patients: The median increment in EDSS was 2.8 points with 
considerably heterogeneity (range: 0  7 points). Only two patients who did not demonstrate 
obvious gait disturbances before remained unaffected in their motor function (patients #6B 
and #14P). All other 12 patients deteriorated further; 10 (71%) of them were at least 
temporarily unable to walk more than few meters even with aid (EDSS ≥ 7). With the 
exception of patient #14P, bladder (and sphincter) dysfunction also became apparent or 
aggravated during the transplant period, especially with fever caused by serotherapy or 
infection. (similar to the Uhthoff phenomenon observed in multiple sclerosis). Two patients 
developed seizures during the transplant procedure. Deterioration of neurocognitive function, 
significant hearing or vision impairment as well as severe disorientation and somnolence 
occurred in five patients (36 %) during early posttransplant phase, four of whom 
subsequently died. In addition Moderate to severe behavioural changes were observed in 11 
men (79 %), which improved markedly or disappeared in all surviving patients after 6  12 
months. 
Patients with limited AMN at admission for transplantation (EDSS < 6) developed 
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significantly fewer neurological symptoms (other than progressive motor disability) compared 
to the ones with advanced AMN (1/9 = 11 % versus 4/5 = 80 %; z = 2.001,  = 0.045).  
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The detailed longterm followup for each patient is listed in table 4, excluding the three 
patients who died within the first 6 months posttransplant. While Three patients 
progressively deteriorated in all functions during the first year postHSCT and died from 
ACALD progression 16 to 36 months after transplant.  
Eight patients stabilized beyond 6 months postHSCT and became longterm survivors. 
Among these eight survivors Two of these did not deteriorate during the transplant procedure 
and showed a stable motor function thereafter. Exacerbation of motor disability during the 
first 6 months posttransplant partly reversed in the other six patients. But However, only 
three men (21 % of all transplanted patients) could walk without assistance (EDSS < 6) 24 
months after HSCT. while Patient #1B was still unable to walk more than a few meters even 
with aid (EDSS = 7). The median gain in EDSS in these men was 1.5 points (range 0.5  5 
points) compared to baseline status. After 24 months postHSCT, motor function further 
improved in four patients, while two deteriorated and two remained stable. Although Bladder 
dysfunction also improved partly over time, but five of the eight patients showed deterioration 
in comparison to the preHSCT status. 
In contrast to motor and bladder function, basic cognitive functions were preserved in all 
surviving patients. Pure intellectual function remained stable in five patients (36 % of all 
transplanted patients): IQ testing was unchanged in three patients (#3B, #5B, and #6B). 
Patient #11P had unaltered cognitive function, but was classified as “moderate deterioration” 
due to significant visual loss. Three other surviving patients (#1B, #7B and #10B) showed a 
moderate cognitive decline. The deterioration in information processing and learning aptitude 
in patient #10B may also been influenced by prior excessive drug abuse. Among the five 
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patients, who had maintained their vocational status prior to HSCT, two (patients #6B and 
#14P) continued as students, one (patient #11P) was unable to resume work due to severe 
motor dysfunction and visual loss and two died following HSCT (patients #2H and #9B).

IQ before HSCT was not predictive for outcome: the five patients with proven or suspected 
cognitive impairment before transplantation (patients #1B, #3B, #4S, #7B, and #14P) had a 
variable transplant course and outcome after HSCT.  
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The Loes MRI severity score varied considerably both at onset of ACALD and before HSCT.  
When ACALD was detected, median Loes score was 4.5 points (range 2 – 12 points) of 
maximum 34 points. The four patients with ACALD at first MRI examination (#1B, #3B, 
#4S, and #7B) tended to have a somewhat higher overall Loes score (median 7.8 points, range 
4 – 9 points).  Loes score increased during the time period between first detection of ACALD 
and HSCT to a median 6.5 points (range 2 – 14 points;  = 0.004). Five patients remained 
stable, while in six patients (#1B, #4S, #5B, #7B, #8B, and #12P) a progression of cerebral 
demyelination resulting in deterioration of at least 2 points was observed. There was no 
correlation with progression in Loes score and that of EDSS, AACS, or in Rankin score 
before HSCT. For the 10 patients with MRI scans performed 6 – 36 months before the onset 
of ACALD, the median Loes score progression rate was 1.2 points per year (range 0 – 5.3 
points). For the 12 evaluable patients, the median Loes score progression rate between onset 
of ACALD and HSCT was 2 points per year (0 – 6 points). 
Due to early death or poor condition, three patients did not have MRI followup (cp. table 3). 
Only patient #1B showed minimal contrast enhancement 6 months postHSCT. None of the 
11 patients examined beyond 6 months after transplant showed further gadolinium 
enhancement of cerebral demyelinating lesions. There was no significant increase in Loes 
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score beyond 12 months postHSCT in comparison to Loes score before HSCT among the 
eight survivors (median 8 points (range 2.5 – 12 points) before HSCT; median 10 points 
(range 5 – 12 points) > 12 months postHSCT).  
The three patients with late death after HSCT tended to show a greater increase in Loes score 
(median gain 4 points; range 1.5 – 18 points) compared with the four experiencing moderate 
deterioration in cognitive function (median gain 1.5 points; range 0  9.5 points) and the four 
with stable cognitive function (median gain 0.8 points; range 0.5 – 2 points). Similarly, New 
demyelinating lesions after HSCT were detected in only one of the four cognitively stable 
patients, whereas lesion progression and new lesions were seen in all three patients 
experiencing late mortality. However, none of these differences were not significant. 
Based on MRI appearances analysis, 10 patients (71 %) showed involvement of pyramidal 
long tract fibers, reflecting AMN (cp. table 1). With regard to ACALD, only seven out of 14 
patients (50 %) were characterized by the typical parietooccipital pattern without additional 
involvement of other structures than pyramidal long tract fibers. Among the other seven 
patients, three patients (21 %) demonstrated predominant involvement of the frontal lobe 
white matter, while four patients (29 %) showed relevant demyelinating lesions in even other 
structures (basal ganglia or cerebellum). Although two of the latter (patients #4S and #5B) 
displayed additional parietooccipital involvement, they were classified as an atypical pattern. 
In contrast to the Loes score itself, the MRI demyelination pattern seemed to have an impact 
on HSCT outcome: Among the 12 men engrafting (cord blood transplantations excluded) the 
estimated survival of ACALD patients displaying the typical parietooccipital pattern (with or 
without projection fiber involvement;  = 6) was 100 % versus 33.3 ± 19.2 % ( = 6; logrank 
test 5.57,  = 0.018) for all other patterns.  
MRI appearances were further analysed according to the study of Eichler et al. (Eichler et al., 
2007): Patient #9B had corticospinal tract involvement without corpus callosum involvement, 
eight patients (#1B, #3B, #4S, #7B, #8B, #10B, #13P, and #14P) had corticospinal tract 
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involvement with additional involvement of the splenium or genu, and five patients (patients 
#2H, #5B, #6B, #11P, and #12P) had no corticospinal tract involvement but other white 
matter lesions within the brain. Aside from an increased EDSS in the nine patients with 
corticospinal tract involvement (median EDSS 5.0 versus 2.9), there were no significant 
differences in age, ratio of progression, rate of lesion progression as well as outcome 
compared with the other patients. However, the five patients (#1B, #4S, #8B, #9B, and #13P) 
with advanced corticospinal tract axonopathy involving the two internal capsules were older 
at ACALD onset, had all an EDSS ≥ 6 before HSCT, and had a significantly poorer post
transplant survival compared with the unaffected patients with a trend for a faster rate of Loes 
score progression before HSCT among these patients (details summarized in table 5). In this 
cohort, the factor bilateral involvement of internal capsule identified the same subgroup of 
patients as the criterion EDSS ≥ 6 just before HSCT (cp. Fig. 1C). 
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To further analyze neurological status between patients with excellent versus poor survival 
further propability, patients were divided into two groups depending on motor disability 
before HSCT and early transplant complications, i.e. lifethreatening to fatal infections during 
the first 6 months posttransplant and/or graft rejection: 
Group I ( = 6) included patients #3B, #5B, #6B, #7B, #10B, and #14P with limited AMN 
symptoms preHSCT (EDSS < 6) and absence of severe early transplant complications. 
Group II ( = 8) included five patients (#1B, #4S, #8B, #9B, and #13P) with advanced AMN 
before HSCT (EDSS ≥ 6) and three patients (#2H, #11P, and #12P) with severe transplant 
complications. 
There was a significant survival advantage for group I patients with 100 % in comparison to 
group II patients with 25.0 ± 15.3 % (logrank test 7.06;  = 0.008; Fig. 1D). Neurological 
and disability status of both patient groups was quantitatively assessed before as well as early 
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(< 6 months) and late (approximately 24 months) after HSCT using EDSS, AACS, modified 
Rankin, and Loes score (table 6). Because The extent of motor dysfunction was a major 
criterion to define both groups, consequently the median EDSS at baseline tended to be 
different between both groups (though not significantly). Patients in both groups deteriorated 
during the early postHSCT period in both motor and bladder function as well as cognitive 
function, reflected by an increase in EDSS (not significant for group I), AACS, and modified 
Rankin score. Relevant Differences between both groups became apparent during the long
term followup: all six patients in group I survived and partly recovered, i.e. these patients had 
a 67 % and 50 % chance fully to preserve cognitive and motor function, respectively (table 4), 
and did not demonstrate significant differences in EDSS, AACS, and modified Rankin score 
late posttransplant in comparison to baseline status. In contrast, the majority of group II 
patients steadily deteriorated and died while the two longterm survivors remained moderately 
to severely impaired both in their motor and cognitive function (patient #11P had only visual 
impairment with preserved cognitive functions). Accordingly, late postHSCT status was 
significantly different between group I and II patients for EDSS and AACS score. There was 
no significant difference in Loes score, but data were either missing ( = 3) or only available 
from 8 months postHSCT ( = 1) for half of the group II patients.  
 
Of the five patients with an EDSS ≥ 6 before HSCT, only patient #1B survived experiencing 
further cognitive decline (Fig. 2). A baseline EDSS < 6 identified a group of nine patients 
with overall good survival.  However, cognitive decline between diagnosis of ACALD and 
transplantation was associated with further cognitive deterioration posttransplant (patient # 
7B). For the remaining eight patients, transplant complications had a major impact on 
outcome. In the absence of transplant complications, all five patients survived with stable 
cognitive function, whereas of the three patients who experienced lifethreatening infections 
and/or graft rejection, only patient #11P survived with loss of vision.  
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This retrospective study of 14 ACALD men provides proofofprinciple that allogeneic HSCT 
can arrest inflammatory cerebral demyelination allowing survival with preserved 
neurocognitive function, at least in a subgroup of patients. The estimated mean survival time 
of the engrafted 12 patients was 81 months, in contrast to 37  41 months reported for 
untreated patients with cerebral demyelination before (van Geel	
, 2001; de Beer	
, 
2014). Moreover, four patients in our series (29%) maintained a completely stable intellectual 
function, and another four developed only moderately impaired neurocognition over a median 
followup period of more than 5 years. Patients who did not progress during 6 to 12 months 
posttransplant became longterm survivors with preserved cognitive function but in most 
cases severe despite ongoing AMN symptoms. The results of HSCT therefore appear with 
regard to survival and cognition may to be similar to that observed in CCALD patients 
(Mahmood 	
 , 2007), provided the procedure if transplant is performed in patients with 
stable cognitive function as well as limited AMN symptoms. before transplant The relatively 
long median time lag interval between first detection of CNS inflammation ACALD and 
HSCT of 9 months in comparison to 5.1 months in boys with CCALD (Miller	
, 2011) 
along with refined transplantation protocols may offer future improvement.  
 
Transplant outcome for adults with ACALD is presumably dependent on both neurological 
baseline status before HSCT as well as the transplant procedure itself.  
With regard to factors that may help to optimise the HSCT procedure The small number of 
patients allows for only cautious comments regarding factors that may improve outcomes. 
Similar to established paediatric protocols, most of our adult cohort were treated with a 
myeloablative busulfan and cyclophosphamide based regimen which confirmed the 
feasibility of engraftment. Under these conditions, using bone marrow as stem cell source 
appeared to be the best single predictor for survival in this series. However, this conclusion 
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may be biased because of confounding factors related to patients treated with peripheral and 
cord blood stem cells. 
Graft failure occurs more frequently with HLAmismatched grafts compared to matched 
donors (relative risk 7.6), in nonmalignant versus malignant diseases (relative risk 3.3), and 
after reduced intensity conditioning compared to myeloablation (relative risk 2.6) (Olsson	

, 2013). According to the same study, graft failure in nonmalignant disorders had no effect 
on survival, whereas graft rejection in our series was associated with death. Moreover, In 
CCALD, immunoablation alone without donor engraftment does not prevent progression of 
disease in CCALD (Nowaczyk 	
 , 1997; Miller 	
 , 2011). Unrelated cord blood 
transplantation after myeloablation may be effective in boys with CCALD lacking a matched 
donor (Beam	
, 2007; Miller	
, 2011). In these studies, however, the overall survival 
of patients receiving cord blood cells was inferior to other stem cell sources. Therefore, there 
should be caution regarding unrelated cord blood for ACALD transplant candidates lacking a 
matched donor, at least with a reducedintensity conditioning regimen. A promising future 
alternative option for patients without a closely matched donor may be genemodified 
autologous hematopoietic stem cell transplantation (Cartier	
, 2009). 
In our series, the two patients who had peripheral blood stem cell transplantation did not 
survive. Although the reason for failure was most likely due to AMN related immobility with 
subsequent lifethreatening infections, peripheral blood stem cells may also have a negative 
impact. Transplantation with peripheral blood stem cell in comparison to bone marrow 
usually results in faster engraftment, more GVHD (Holtick	
, 2015) and higher mortality 
in nonmalignant diseases (Bacigalupo 	
 , 2015). In ACALD patients, prevention of 
GVHD may be of particular importance. Rapid clinical deterioration after the onset of severe 
acute GVHD has been observed in CCALD patients (Peters	
, 2004; Miller	
, 2011) 
and in a patient with ACALD (Fitzpatrick 	
 , 2008). In addition, chronic GVHD was 
associated with temporary deterioration in motor function of an adult patient (Hitomi	
, 
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2005). Although overall GVHD incidence in this series was low compared to other transplant 
patients (Socie 	
 , 2011), the only case of significant acute GVHD was observed after 
peripheral blood stem cell transplantation.  
In summary, we therefore recommend the use of a myeloablative, busulfanbased 
conditioning regimen in combination with bone marrow for transplanting ACALD patients 
(see box). However, we recognise that future research could focus on potential improvements 
in the conditioning regimen using other agents to reduce the toxicity of the procedure. 
 
In addition to transplantrelated factors, the neurological baseline status of ACALD patients 
also determines the outcome after allogeneic HSCT. In boys with CCALD undergoing HSCT, 
more deaths resulted from disease progression in advanced patients than from transplant 
related problems (Peters	
, 2004). Although transplantrelated mortality in adult patients 
caused by infection or GVHD may be as high as 30 % (La Nasa	
, 2005; Gooley	
, 
2010; Peffault de Latour	
, 2012; Bacigalupo	
, 2015), a survival of less than 60 % in 
transplanted ACALD patients suggests additional ALDspecific problems. However, an 
analysis of the impact of neurological status in adults is complicated by the fact that the 
clinical phenotype of ALD men is usually a combination of ACALD itself plus accompanying 
AMN symptoms.  
With regard to In ACALD, preserved cognitive function before HSCT was considered to be 
important for stable longterm outcome. The four patients with progressive cognitive decline 
between ACALD diagnosis and HSCT, who already displayed cerebral symptoms such as 
impaired vision and hearing, attention deficits, or seizures before transplant, suggest a disease 
stage too advanced for satisfactory outcomes from HSCT. this is the case history of an This is 
consistent with a previouslyreported Irish adult patient with advanced disease ACALD 
(Fitzpatrick 	
 , 2008) and boys with symptomatic CCALD. Such patients probably best 
compare to symptomatic CCALD boys 
The latter display an inferior survival and a greater 
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risk for neurological decline after HSCT than nearly asymptomatic or presymptomatic 
CCALD patients (Peters	
, 2004; Miller	
, 2011). Moreover, patients who deteriorate 
in their cognition during the few months prior to HSCT may simply reflect a highly 
aggressive cerebral disease. In contrast, the two patients (#3B and #14P) with suspected 
deterioration in intellectual function before the diagnosis of ACALD but subsequent 
stabilisation prior to HSCT displayed a stable cognitive function postHSCT. These courses 
may indicate cerebral disease with less aggressive dynamics than expected. Uncertainty about 
the IQ before the onset of ACALD in four patients did not allow definition of a baseline IQ
value as predictor of outcome in this small cohort. 
While the Loes score seems to be a valuable predictor of survival and outcome of HSCT in 
boys with CCALD (Peters 	
 , 2004; Miller 	
 , 2011; McKinney 	
 , 2013), 
particularly for the typical parietooccipital demyelination pattern (McKinney	
, 2013), it 
does not appear to have the same utility in ACALD. In the adults of our series, “atypical” 
demyelination patterns were observed in 50 % of patients, far more frequent than in childhood 
with 20 – 30 % (Loes	
, 2003). Whether uncommon MRI patterns and changes in Loes 
scores immediately prior to transplant predict a poorer survival for ACALD men after HSCT 
has to be confirmed.  per se inflict a poorer survival for ACALD men after HSCT, as 
indicated in this series, has to be confirmed by a larger number of patients. In addition a larger 
study has to reveal whether an increment in  In addition a larger study has to reveal whether 
an increment in Loes score immediately before transplant may be a more useful predictor for 
poor outcome than a high, but stable Loes score: a rapid increase in Loes score between 
diagnosis of ACALD and HSCT seem to better predict neurologic deterioration (e.g. patient 
#4S) than extended demyelinating lesions before diagnosis of inflammatory disease which do 
not show any further increase before transplant (e.g. patient #14P).  
Independent from Loes score, lesion progression in adult patients with XALD has been 
highly associated with corticospinal tract involvement with a mean progression rate of 1 point 
Page 27 of 53
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
every 10 months (Eichler 	
 , 2007). In our cohort, lesion progression before HSCT was 
observed in an overall higher percentage of patients (71 %) independent of corticospinal tract 
involvement, most likely because gadolinium enhancement was the prerequisite to select 
patients for transplantation. Contrast enhancement appears to correlate even better with 
rapidly progressive MRI lesions; median progression rate of Loes score in all 14 adult patients 
before HSCT was 2.0 points per year (range 0 – 6 points), as high as in children with cerebral 
XALD (Loes 	
 , 2003) and at a greater rate than previously reported for adults with 
corticospinal tract involvement (Eichler 	
 , 2007). Corticospinal tract involvement alone 
failed to detect a highrisk group of patients in this series. However, bilateral involvement of 
the internal capsules identified a subgroup of patients with higher age and EDSS at HSCT as 
well as a poorer prognosis after transplantation in comparison to all other patients. There was 
also a trend for more rapid lesion progression brain demyelination and possibly also a longer 
history of AMN before ACALD in this patient group. 
Bilateral involvement of the internal capsules may therefore mark an endstage of ascending 
axonopathy in adult males with AMN. Further studies are needed to determine if AMN 
patients with isolated bilateral involvement of internal capsules develop more severe AMN 
symptoms and are at highrisk to develop ACALD, and, if so, more rapidly progressive 
ACALD. Our study suggests, however, that ACALD patients with bilateral involvement of 
the internal capsules have a significantly poorer prognosis after transplant with little benefit, if 
any, from HSCT. 
Advanced AMN, reflected by bilateral involvement of both internal capsules, may contribute 
appeared to be of at least similar importance for survival than extensive ACALD. in this 
series. Severe motor deficits of the lower limbs prior to transplant were frequently associated 
with immobility and lifethreatening infections during the transplant procedure. and 
subsequently. Specifically, poor baseline motor function (EDSS ≥ 6) conferred higher 
morbidity for survivors, even long after transplantation.
 Whether some patients became 
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psychiatric problems is almost impossible to determine. On the other hand, lifethreatening 
infections and/or nonengraftment may result in severe secondary cerebral disease progression 
even in patients with limited AMN symptoms prior to transplantation.  
It is noteworthy, that Nearly all patients in this cohort developed behavioural changes such as 
disinhibition or depression at least transiently in the early posttransplant period (Rosebush	

, 1999; Chee	
, 2013), which were associated with an additional burden on the patients, 
and their families, potentially creating additional logistical pressures and on the adult 
transplant unit. After transplant, these behavioural changes led to fractured relationships. The 
short and long term psychosocial consequences of delivering HSCT to ACALD patients and 
their families require future consideration. 
 
In conclusion, This study indicates for the first time the feasibility, complications and 
potential longterm neurological benefit of allogeneic HSCT in ACALD. The poor prognosis 
of patients with advanced AMN symptoms (EDSS ≥ 6) may relate to 1) immobility during the 
transplant procedure with increased risk of infections, 2) predisposition to rapidly progressive 
ACALD due to corticospinal tract involvement within the internal capsules, and 3) cognitive 
decline and/or psychiatric problems during the transplant procedure that complicates the 
management of patients during the transplant procedure. Based on our limited experience, we 
propose preliminary and tentative recommendations for HSCT in ACALD patients (see box). 
Further studies are warranted to improve outcomes through careful patient selection and 
optimisation of HSCT protocols. Given the rarity of this disease, it is essential to have clear 
referral pathways to specialist centres able to assess and treat patients without delay. 
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(A) Survival of all 14 patients. (B) Patients stratified by stem cell source, i.e. bone marrow 
versus peripheral blood stem cells or cord blood. (C) Patients stratified by extent of motor 
dysfunction (EDSS) at admission for HSCT. (D) Patients stratified for EDSS at admission for 
HSCT and occurrence of lifethreatening or fatal infections during first 6 months post HSCT.  
Dots on probability lines indicate censored patients. 
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OS = overall survival; EFS = eventfree survival, i.e. no cognitive decline post HSCT. 
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1) Men at risk of developing ACALD should be routinely monitored by a 
multidisciplinary team (neurologists, metabolic physicians and transplant 
haematologists) in specialized centres. 
2) Potential family donors should be identified in advance to save time once 
inflammatory cerebral demyelinating lesions (i.e. with contrast enhancement) occur at 
are identified on brain MRI. 
3) Stable neurocognitive function prior to transplant and limited AMN symptoms (EDSS 
< 6) are favourable outcome parameters.  
4) Patients with bilateral involvement of the internal capsule on brain MRI do not seem 
to benefit from HSCT. 
5) Stem cell source: bone marrow from a matched related or unrelated donor (≥ 9/10 
HLA6match confirmed by high6resolution typing) is preferred over peripheral blood 
stem cells or cord blood. 
6) HSCT procedure: busulfan based ‘full intensity’ or ‘myeloablative’ conditioning 
regimens should be used, combined with serotherapy (e.g. antithymocyte globulin) to 
promote engraftment and limit GVHD. All efforts should be made to prevent fever 
due to serotherapy or infections, which may be associated with acute neurologic 
deterioration. 
7) Patients should be treated in experienced transplant centres and registered with the 
European Group for Blood and Marrow Transplantation (EBMT), the Center for 
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International Blood and Marrow Transplantation Research (CIBMTR) or equivalent 
transplant registries.  
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Table 1: Patients demographics and disease characteristics 
#
a
 Age at 
ACALD  
[years] 
EDSS
Score
b
 
(max. 10) 
Addison’s 
Disease 
MRI pattern
c
 
Occipital/frontal/ 
pyramidal tracts/others 
Loes
Score  
(max. 34) 
Clinical symptoms ( @ age in years) 
 
11P 23 1 Yes + /  /  /  2.5 Addison’s disease (10), mild spastic paraplegia (24) 
01B 
 
45 6.5 No ++ /  / ++ /  7 Sensory symptoms (44.4), spastic paraplegia (45.5), CNS 
symptoms: attention deficit, disinhibition (46.1).  
Gadolinium enhancement on 1
st
 MRI 
4
 
12P 27 4 Yes ++ /  /  /  5.5 Addison’s disease (16), mild spastic paraplegia (25) 
02H 48 2.5 Yes  / + /  /  2 Addison’s disease (18.6), mild spastic paraplegia (45.6) 
03B 35 
 
3.5 No ++ /  / + /  9.5 Intermittent bladder dysfunction (33.0), spastic paraplegia (35.2). 
Gadolinium enhancement on 1
st
 MRI 
04S 32 7 Yes ++ / + / ++ / +  
(temporal, thalamus) 
14 Family screening (24.8)
 
, lost to followup; CNS symptoms: 
impaired hearing/vision (prosopagnosia, field defect), dysphasia, 
ataxia (31.9), Addison’s disease (33.4). Weight loss 
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#
a
 Age at 
ACALD  
[years] 
EDSS
Score
b
 
(max. 10) 
Addison’s 
Disease 
MRI pattern
c
 
Occipital/frontal/ 
pyramidal tracts/others 
Loes
Score  
(max. 34) 
Clinical symptoms ( @ age in years) 
 
13P 42 6 No  /  / ++ / +  
(centrum semiovale) 
5 Family screening (35)
 
, spastic paraplegia (35)  
  
05B 33 4 No + / (+) /  / ++ (olivo
pontocerebellar atrophy) 
9 Ataxia (25.5), spastic paraplegia (30), severe bladder dysfunction.  
Weight loss 
06B 31 3 Yes (+) / + /  /  6 Addison’s disease (17.0), sensory symptoms (25.6), CNS 
symptoms: mild attention deficit, mild impaired vision (field 
defect) (31.8) 
14P 21 1 No ++ /  / + /  12 CNS symptoms: learning difficulties (14.5), family screening 
(18.8)
 
 . Cerebral demyelination without Gadolinum enhancement 
on 1
st
 MRI 
07B 32 4 No ++ /  / + /  11 Spastic paraplegia (31.3), CNS symptoms: seizure (32.4), attention 
deficit, dysarthria (32.8), impaired vision. Weight loss.  
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#
a
 Age at 
ACALD  
[years] 
EDSS
Score
b
 
(max. 10) 
Addison’s 
Disease 
MRI pattern
c
 
Occipital/frontal/ 
pyramidal tracts/others 
Loes
Score  
(max. 34) 
Clinical symptoms ( @ age in years) 
 
Gadolinum enhancement on 1
st
 MRI 
08B 42 6.5 Yes  / ++ / ++ /  10.5 Spastic paraplegia (23.8), Addison’s disease (25.8), CNS 
symptoms: disinhibition, attention deficit (42.4). Weight loss 
09B 46 6.5 No  / + / ++ / + (cerebellum) 4.5 Spastic paraplegia (24.0), ataxia (44.5). Weight loss 
10B 25 4 No + /  / + /  5 Family screening (14.4)
 
, spastic paraplegia (21.4), drug abuse (23)  
 
To table 1: 
a 
#: Patients in order of transplantation date. Capital letters indicate transplant center: P = Paris, B = Berlin, H = Hannover, S = Sheffield.  
b 
EDSS: Kurtzke Expanded Disability Symptom Score (EDSS) just prior to HSCT.  
c 
MRI pattern: MRI lesions differentiated for involvement of parietooccipital, frontal, pyramidal long tract fibers in internal capsule or pons, and 
other white matter as indicated. Degree of involvement: , no; +, moderate; ++, extensive. 
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Table 2: Patients hematopoietic stem cell transplantation characteristics 
# 4 
ACALD  
to HSCT 
[Months] 
Conditioning Donor Source Donor chimerism 
(Day +100:   
>90% donor) 
Acute 
GVHD 
Significant 
Infection 
Other  significant 
nonneurological toxicity 
Outcome 
11P 6 MAC+S MSD BM Yes Grade I Life
threatening 
Hemorrhagic cystitis (HC), 
thrombotic microangiopathy 
Alive 
01B 8 MAC+S MSD BM Yes No   Alive 
12P 12 RIC+S UD 1xCB Not tested  
(aplastic) 
N/A Fatal 
(fungal) 
 Dead  
(TRM) 
02H 3 MAC+S MUD BM Yes Grade I Life
threatening 
Transient multiorgan failure 
(MOF) 
Dead  
(Progress) 
03B 14 MAC+S MUD BM Yes No Severe  Alive 
04S 15 MAC+S MSD BM Yes No   Dead  
(Progress) 
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# 4 
ACALD  
to HSCT 
[Months] 
Conditioning Donor Source Donor chimerism 
(Day +100:   
>90% donor) 
Acute 
GVHD 
Significant 
Infection 
Other  significant 
nonneurological toxicity 
Outcome 
13P 9 RIC UD 2xCB Yes (Day +60)
 
 
No (<1% donor later)
 a
 
No Life
threatening 
Immune nephrotic syndrome, 
endstage renal failure
 1
 
Dead  
(Progress) 
05B 9 MAC+S MUD BM Yes No Severe  Alive 
06B 11 MAC+S MUD BM Yes Grade I   Alive 
14P 6 MAC MUD BM Yes No   Alive 
07B 12 MAC+S MUD BM Yes Grade I Severe Pneumonia Alive 
08B 9 MAC+S MUD PBSC Yes No Life
threatening 
Pneumonia, HC, polyserositis, 
multiorgan failure 
Dead  
(TRM) 
09B 5 MAC+S MUD PBSC Not tested Grade 
IV 
Fatal Sepsis/pneumonia, HC, multi
organ failure 
Dead  
(TRM) 
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# 4 
ACALD  
to HSCT 
[Months] 
Conditioning Donor Source Donor chimerism 
(Day +100:   
>90% donor) 
Acute 
GVHD 
Significant 
Infection 
Other  significant 
nonneurological toxicity 
Outcome 
10B 11 MAC+S MUD BM No (80 % donor) Grade I   Alive 
 
To table 2: 
4 ACALD to HSCT: Time interval between first detection of gadolinium enhancement in MRI (onset of ACALD) and HSCT in months. 
Conditioning: MAC (+S) = myeloablative conditioning (plus serotherapy), i.e. busulfan 16 mg/kg orally (or busulfan i.v. targeted dose in patient 
#14P) and cyclophosphamide (120 mg/kg over 2 days or 200 mg/kg over 4 days) (plus rabbit antithymoglobulin Genzyme® or Fresenius® ).  
RIC (+S) = reduced intensity conditioning (+serotherapy), i.e. clofarabine 200 mg/m², busulfan 4 mg/kg orally, melphalan 140 mg/m², and 
alemtuzumab in patient #12P; cyclophosphamide 50 mg/kg, fludarabine 200 mg/m², total body irradiation with 2 Gy in patient #13P. 
Donor: MSD, matched sibling donor; (M)UD, (matched) unrelated donor. 
Source: BM, bone marrow, PBSC, peripheral blood stem cells, CB, cord blood with one (1x) or two (2x) units. 
Acute GVHD: Acute graftversushost disease with maximum grade.  
Significant infection: refers to at least severe toxicity (grade ≥3) according to the National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events version 3.0 (CTCAE v.3.0) criteria.  
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Significant nonneurological toxicity: refers to at least severe toxicity (grade ≥ 3) according to CTCAE v.3.0 criteria. HC, hemorrhagic cystitis. 
MOF, multiorgan failure. 
Outcome: TRM = transplantrelated mortality, progress = ACALD progression 
a 
Patient #13P: initially autologous hematopoietic regeneration, since day +30 detection of mixed donor chimerism (maximum >90 % at day +60, 50 
% donor at day +120, thereafter <1 % donor chimerism). Toxicity due to allogeneic CB transplantation/nonengraftment suspected.  
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Table 3: Disease status within 6 months after allogeneic hematopoietic stem cell transplantation and MRI outcome 
 
# EDSS 
before 
Early postHSCT changes  
@ months post HSCT 
EDSS 
@06 
MRI outcome  
@months post HSCT 
11P 1 Motor dysfunction ↑↑ immediately after tx, walks only few meters with 2 
crutches @6; bladder dysfunction ↑↑ (parallel to BK virus cystitis); behavioral 
disinhibition until @12; vision↓  
7 New lesions and progression,  
LS 12 @13; 
thereafter stable 
01B 6.5 Conditioning: walks only few steps without help until @3; fever after 1
st
 
serotherapy: seizure, bladder/stool incontinence (until @1);  
severe depression until @6  
8 No change, minimal Gd+,  
LS 7(stable) @6; 
new lesions (frontal), LS 10 @18 
12P 4 Motor/bladder dysfunction stable until shortly before death in aplasia (transplant 
related (TRM)) @2; severe behavioral changes 
7 Not tested 
02H 2.5 Sepsis after 1
st
 serotherapy: seizure, disorientation, coma, renal failure, bedridden 
@1; major improvement until @3; still walks only with 2 crutches; thereafter 
further deterioration   
9.5 Many new lesions (PO,frontal,CC), LS 
14 @6; 
progression & atrophy, LS 20 @12 
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03B 3.5 Sepsis @0.5: bladder/stool incontinence, agitated; walks only few steps w/o aid 
@1; thereafter motor/bladder function↑; moderate disinhibiton 
6.5 Moderate lesion progression (PO),  
LS 11 @16;  
stable, CC atrophy, LS 12 @59 
04S 7 Motor dysfunction↑↑, hemiplegic @3; vision↓; complete hearing loss@2; major 
confusion/psychosis@1; severe depression@6; no further deterioration @36 
8.5 Lesion progression, +atrophy,  
LS 15.5 @8 
13P 6 Spastic paraparesis ↑; moves from wheelchair to bed with difficulties @6; 
bladder dysfunction stable; severe behavioral changes 
8.0 New lesions and progression,  
LS 8 @12; 
minimal progression, LS 9 @24 
05B 4 Conditioning: Gait ataxia↑, needs urine catheter; walks only few steps w/o aid 
@1, thereafter motor function(↑); moderate depression until @6;   
6.5 New lesions (PO, frontal), LS 11.5 
@7; less lesions detected (PO, CC, 
visual), LS 8.5 @34 
06B 3 Normal motor function; minimal bladder dysfunction unchanged; moderate 
disinhibition @1 
3 New lesions (PO), LS 8 @6;  
no change @37 
14P 1 Normal neurological function preserved; severe behavioural disinhibition @6  1 No progression, LS 12 (stable) @14 
07B 4 Sepsis @0.5: walks only few steps with aid, bladder incontinence, attention 7.5 Lesion progression, LS 12 @9; 
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deficit; able to walk 300m/bladder function↑@6; major depression until @6; 
anticonvulsive prophylaxis 
less lesions detected, LS 10 @24 
08B 6.5 Conditioning: motor dysfunction ↑, bladder/stool incontinence; sepsis @0.5: 
bedridden, disoriented, “frontal brain syndrome”, cognition↓; continued decline 
until death@4 (TRM)   
9.5  Not tested 
09B 6.5 Conditioning: severe dizziness, bladder/stool incontinence, dysarthria; 
sepsis@day 2: can not stand; bedridden; GVHD@ day 7: severe disorientation, 
hallucination; death@0.5 (TRM)   
9.5 Not tested 
10B 4 No significant change @1; ataxia↑@3 (needs bilateral aid); rarely stool 
incontinence @6 
6.5 Internal capsule↑, LS 5 (stable) @38 
 
To table 3:  
EDSS@06 = maximum EDSS score during first 6 months post HSCT. 
MRI: LS = Loes score, PO = paritooccipital, CC = corpus callosum  
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Table 4: Longterm disease status after allogeneic hematopoietic stem cell transplantation 
 
# EDSS 
before 
Longterm outcome  
@ months post HSCT 
EDSS 
@ 24 
months 
Motor 
function 
>36 
months 
Follow
up 
(months) 
11P 1 Disinhibition resolved @12; cognition stable (PIQ 89), but visual loss (1/10, 2/10 with 
major cuts in visual fields)@18; motor function slowly improved after @24 (walks 500m 
with 1 crutch @108); severe bladder dysfunction unchanged; good QoL despite motor and 
visual handicap     
6 ↑ 116 
01B 6.5 Depression improved @12; motor dysfunction (↑) @12: transfers alone to wheelchair; 
moderate bladder dysfunction unchanged; cognition↓ (IQ 75) @20; teaches at handicapped 
institution; no changes after @24  
7 = 92 
02H 2.5 Deterioration in all functions since @3; unable to walk unassisted @6; diabetes 
mellitus/chronic inflammation @12; rapid further deterioration; death from secondary 
ACALD progression at @16 
10 N/A (16) 
Page 48 of 53
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
         
       12 
03B 3.5 Behavioural changes resolved @12; Cognition stable (IQ 99) @16; walks without aid >500 
m @53; limited bladder dysfunction unaltered; completely stable @88; good QoL; retired 
due to spasticity. 
4 ↑ 88 
04S 7 Depression improved @12; further deterioration in motor/bladder/cognitive function after 
@6; death from ACALD progression @24 
10 N/A (24) 
13P 6 Repeated septicemias under dialysis after @6; paraplegic, unable to transfer from bed to 
wheelchair alone, can speak and understands, but severe cognitive decline @24; very poor 
QoL, aware of his status; death from secondary ACALD progression at @36 (also related 
to nonengraftment) 
9 N/A (36) 
05B 4 Best clinical status @12: able to walk 200m unassisted; requires crutch for walking @41; 
severe bladder dysfunction unaltered; cognitive function stable (PIQ 108) @12; 
depression↓↓, but moody; still unemployed 
6 ↓ 72 
06B 3 Stable neurocognition: IQ 111 @13; no relevant change until @31; motor function ↑: 
walks >5 km @59; no bladder dysfunction @59; bachelor completed; information 
processing moderately↓; excellent QoL 
3 ↑ 59 
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14P 1 Severe behavioural disinhibition resolved @12; normal neurological status @14; cognitive 
function stable (IQ 72 before!); back to university (with great difficulties); good QoL   
1 = 43 
07B 4 Best clinical status @12: able to walk 100m unassisted; hemiparesis; requires crutch for 
walking @18; bladder incontinence @18; cognitive function↓ (concentration↓); depression 
improved@12; still low QoL 
6 ↓ 45 
10B 4 Moderate improvement of ataxia after @22 (walks >1 km with bilateral aid); intermittent 
stool incontinence unchanged; cognition: memory↓, attention↓, information processing↓ 
@13; formal thinking↑ @38 (moderate decline in neurocognition also due to drug abuse?); 
retired; good QoL  
6 ↑ 38 
 
To table 4: 
Motor function >36 months (at last followup): ↑ improved, = stable, ↓ deteriorated. QoL = quality of life. 
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Table 5: Characteristics of patients with or without bilateral involvement of internal capsules on brain MRI 
  
 
 
Group A [ = 5]: 
With bilateral involvement of internal 
capsule 
Group B [ = 9]: 
Without bilateral involvement of 
internal capsule 
 
 = 
 
Progressive disease detected 5 out of 5 6 out of 9 ns 
Rate of demyelinating lesion progression 
[Loes score points per year] 
2.9 (1 – 6) 0.6 (0 – 6) 0.078 
Age at ACALD [years] 41.9 ± 5.6 30.7 ± 8.1 <0.05 
Time period AMN to ACALD [months]  90 (15  235) * 27 (24  49) * ns 
Loes score before HSCT 6.0 (4.4  9.9)  7.0 (4.9  11.4) ns 
EDSS before HSCT 6.5 (6.4  6.6) 3.5 (2.1  4.0) <0.01 
Probability of  survival [%] 20 ± 18 * 78 ± 14 <0.015 
To table 5: 
All numbers in bold represent median values (with 25
th
 and 75
th
 percentile). Significance calculated by rank sum test. *Age and probability of 
survival: Mean ± standard deviation. Significance calculated by studentttest (age) or logrank test (survival). ns = not significant.  
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Table 6: Changes in neurological performance scales and MRI severity score before and after HSCT according to baseline status and 
transplant complications 
 
 Group I [ = 6]:: 
Baseline EDSS < 6 w/o transplant complications 
Group II [ = 8]:: 
Baseline EDSS ≥ 6 or early transplant complications
*
  
 Before HSCT Early post HSCT 
[≤ 6 months] 
Late post HSCT 
[approx. 24 months] 
Before HSCT Early post HSCT 
[≤ 6 months] 
Late post HSCT 
[approx. 24 months] 
EDSS  
[max. 10 points]  
3.8 (3.0  4.0) 
 
6.5 (3.0  6.5)  
 
5.0 (3.0  6.0) 
 
6.3 (3.3  6.5) 
 
8.3 (7.5  9.5) 
++ #
 
 
9.0 (6.8 1 0.0)
 ++ #
 
[ = 5] 
AACS 
[max. 24 points]  
7.5 (7.0  10) 13.0 (10.0  15.0)
 ++
 
 
9.0 (7.0  12.0) 
 
11.5 (5.5  12.5) 
 
18.0 (16.5  22.5)
 ++ #
 
 
21.0 (15.8  24.0)
 ++ #
 
[ = 5] 
Modified Rankin 
Score 
2.0 (1.0  3.0) 
 
4.0 (3.0  5.0)
 ++
 
 
3.5 (2.0  4.0) 
 
3.5 (1.5  4.0) 
 
5.0 (5.0  6.0)
 ++ #
 
 
6.0 (4.0  6.0)
 ++
 
[[ = 5] 
Loes Score (MRI) 
[max. 34 points]  
9.3 (6.0 11.0) 
 
 
 
9.3 (8.0  11.0) 
 
5.3 (3.5  8.8)  11.0 (9.5  16.0) 
[ = 4] 
All numbers in bold represent median values (with 25
th
 and 75
th
 percentile). Differences in baseline scores between group I and group II were not 
significant. * Early transplant complications, i.e. at least lifethreatening infections during early transplant phase or graft rejection.  
++ Friedman repeated measures ANOVA on ranks with following pair wise multiple comparisons (Tukey test)):   < 0.05 in comparison to 
respective baseline status before HSCT. Missing values of the three early deceased patients for the late time point were supplemented with the 
respective values from the earlier time point (last value before death) except for Loes score. 
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# KruskalWallis ANOVA on ranks with following multiple comparisons versus control according to Dunn’s method:  < 0.05 in comparison to 
late post HSCT status of group I patients.   
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